Key points from article :
In a major move for the longevity sector, Altos Labs has acquired Dorian Therapeutics, a Stanford University spinout focused on combating ageing through senotherapeutics. The deal, announced by Dorian’s CEO Maddalena Adorno on LinkedIn, marks a significant step toward translating basic science into potential anti-ageing treatments. Though the financial details were not disclosed, the acquisition signals rising momentum in the field of cellular rejuvenation.
Dorian Therapeutics specializes in developing “senoblockers”—small molecules that suppress the harmful effects of senescent cells, which accumulate with age and contribute to disease and tissue decline. These molecules aim to reduce the senescent cell burden and reactivate the body's repair systems, including stem cell function and youthful gene expression. Promising preclinical results have been seen in models of lung fibrosis and osteoarthritis.
Altos Labs, a well-funded player with $3 billion in backing, is known for its work in cellular reprogramming, a technique aimed at restoring cell and tissue function by resetting their biological age. While Altos and Dorian take different scientific approaches, their technologies are complementary—especially in their shared goal of modulating epigenetic pathways to fight ageing.
Though Altos has yet to begin human trials, there’s growing optimism that 2025 will mark the start of clinical testing in this space. The acquisition, alongside efforts by other companies like Life Biosciences, reflects a turning point where longevity science may soon transition from theory to therapy.
